このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Blueprint Medicines マネジメント
マネジメント 基準チェック /34
Blueprint Medicines'の CEO はKate Havilandで、 Apr2022年に任命され、 の在任期間は 2.17年です。 の年間総報酬は$ 6.43Mで、 12.2%給与と87.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.096%を直接所有しており、その価値は$ 6.22M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と9.1年です。
主要情報
Kate Haviland
最高経営責任者
US$6.4m
報酬総額
| CEO給与比率 | 12.2% |
| CEO在任期間 | 2.4yrs |
| CEOの所有権 | 0.09% |
| 経営陣の平均在職期間 | 4yrs |
| 取締役会の平均在任期間 | 9.4yrs |
経営陣の近況
Recent updates
Blueprint Medicines: Growth For The Long Term Still Mostly Priced In
Sep 27Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?
Aug 16
Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S
Jul 23Blueprint Medicines: Overdue For A Breather
Jul 16Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 05Blueprint Medicines: Rampant Growth Mostly Priced In
May 04Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?
Apr 26Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)
Apr 05Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Feb 20Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate
Jan 08Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%
Dec 18Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?
Nov 20Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?
Jul 26Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?
Apr 16Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 09Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt
Dec 12Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
Nov 07Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal
Sep 15Blueprint to seek label expansion for systemic mastocytosis therapy after trial win
Aug 17Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance
Aug 02Blueprint to sell Ayvakit royalty for $250M upfront; Gavreto royalty for $175M upfront
Jun 30CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$205m |
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$6m | US$782k | -US$507m |
| Sep 30 2023 | n/a | n/a | -US$555m |
| Jun 30 2023 | n/a | n/a | -US$554m |
| Mar 31 2023 | n/a | n/a | -US$581m |
| Dec 31 2022 | US$6m | US$701k | -US$558m |
| Sep 30 2022 | n/a | n/a | -US$718m |
| Jun 30 2022 | n/a | n/a | -US$702m |
| Mar 31 2022 | n/a | n/a | -US$650m |
| Dec 31 2021 | US$4m | US$501k | -US$644m |
| Sep 30 2021 | n/a | n/a | -US$411m |
| Jun 30 2021 | n/a | n/a | US$340m |
| Mar 31 2021 | n/a | n/a | US$325m |
| Dec 31 2020 | US$2m | US$461k | US$314m |
| Sep 30 2020 | n/a | n/a | US$333m |
| Jun 30 2020 | n/a | n/a | -US$395m |
| Mar 31 2020 | n/a | n/a | -US$371m |
| Dec 31 2019 | US$3m | US$432k | -US$348m |
| Sep 30 2019 | n/a | n/a | -US$362m |
| Jun 30 2019 | n/a | n/a | -US$340m |
| Mar 31 2019 | n/a | n/a | -US$267m |
| Dec 31 2018 | US$3m | US$393k | -US$237m |
| Sep 30 2018 | n/a | n/a | -US$205m |
| Jun 30 2018 | n/a | n/a | -US$170m |
| Mar 31 2018 | n/a | n/a | -US$177m |
| Dec 31 2017 | US$1m | US$353k | -US$148m |
報酬と市場: Kateの 総報酬 ($USD 6.43M ) は、 US市場 ($USD 8.44M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Kateの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Kate Haviland (48 yo)
2.4yrs
在職期間
US$6,432,012
報酬
Ms. Kathryn Haviland, also known as Kate, M.B.A, is Independent Director of Bicara Therapeutic, Inc. from September 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serv...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 2.4yrs | US$6.43m | 0.095% $ 5.5m | |
| Co-Founder & Director | no data | US$397.33k | 0.11% $ 6.7m | |
| Chief Financial Officer | 8.6yrs | US$2.19m | 0.057% $ 3.3m | |
| Chief Operating Officer | 2.4yrs | US$2.81m | 0.043% $ 2.5m | |
| Chief Scientific Officer | 3.3yrs | US$2.30m | 0.078% $ 4.6m | |
| President of Research & Development | 4yrs | US$2.80m | 0.044% $ 2.6m | |
| Senior VP | 1.7yrs | データなし | 0.024% $ 1.4m | |
| Chief Technical Operations & Quality Officer | 6.9yrs | US$3.79m | 0.053% $ 3.1m | |
| Senior Director & Head of Investor Relations | no data | データなし | データなし | |
| Executive VP | 8yrs | US$2.34m | 0.046% $ 2.7m | |
| Chief People Officer | 4.6yrs | データなし | 0.020% $ 1.1m | |
| Senior Vice President of Corporate Affairs | no data | データなし | データなし |
4.0yrs
平均在職期間
54yo
平均年齢
経験豊富な経営陣: BPMCの経営陣は 経験豊富 であると考えられます ( 3.8年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 2.4yrs | US$6.43m | 0.095% $ 5.5m | |
| Co-Founder & Director | 13.4yrs | US$397.33k | 0.11% $ 6.7m | |
| Chair of Scientific Advisory Board | 12.3yrs | US$333.38k | データなし | |
| Lead Independent Director | 8.4yrs | US$452.33k | 0.017% $ 1.0m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board & Independent Director | 13.4yrs | US$417.33k | 0.088% $ 5.2m | |
| Independent Director | 8.6yrs | US$419.33k | 0.017% $ 1.0m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 2.8yrs | US$422.33k | 0.014% $ 796.1k | |
| Chairman | 10.2yrs | US$526.08k | 0.25% $ 14.4m |
9.4yrs
平均在職期間
62yo
平均年齢
経験豊富なボード: BPMCの 取締役会 は 経験豊富 であると考えられます ( 9.1年の平均在任期間)。